

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,098	07/12/2001	Tugrul T. Kararli	Pharmacia Case 3351.2	1335
26303	7590 10/23/2002			
FLYNN, THIEL, BOUTELL & TANIS, P.C. 2026 RAMBLING ROAD KALAMAZOO, MI 49008-1699			EXAMINER	
			FAY, ZOHREH A	
			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 10/23/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. **09/904,098**

Applicant(3)

Examiner

Kararli et al.

Zohreh Fav

Art Unit 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filled after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (8) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims _____ is/are pending in the application. 4) X Claim(s) 1-40 4a) Of the above, claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) X Claims 1-40 are subject to restriction and/or election requirement. **Application Papers** 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) \square The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) The translation of the foreign language provisional application has been received. 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6) Other:

Application/Control Number: 09/904,098

Art Unit: 1614

Restriction to one of the following inventions is required under 35 USC 129:

Group I, claims 1-28 is drawn to a composition and method of treating a cox-2 mediated

disorder using a cox-2 inhibitory drug classified in class 514, subclass 277.

Group II, claims 29-39 is drawn to a composition and method of treating a cox-2 mediated disorder using a cox-2 inhibitory drug in combination with a second drug, classified in class 514, subclass 277,530 and 573.

Group III, claims 39-40 is drawn to composition and method of treating an eye disorder using a drug of low solubility, classified in class 514, various subclass.

The above delineated inventions are independent and patentably distinct from another. Each of the above group is drawn to totally different components. One practicing the invention of one of the above groups would not be required to practice the inventions of any of the other groups. The search for the above groups would not be co-extensive. Each of the above groups is capable of supporting its own patent. Thus, restriction for examination purpose is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/904,098

Art Unit: 1614

Fay/dl

October 2, 2002

ZOHREH FAY PRIMARY EXAMINER GROUP 1200

Topul For